title: Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Shapiro
authors.forename: Alain H
authors.initials: AH
authors.lastname: Rook
authors.forename: Michael S
authors.initials: MS
authors.lastname: Lehrer
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: Junkins-Hopkins
authors.forename: Lars E
authors.initials: LE
authors.lastname: French
authors.forename: Carmela C
authors.initials: CC
authors.lastname: Vittorio
mesh_terms: D000077610:Bexarotene; D001707:Biopsy, Needle; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007155:Immunologic Factors / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000473:pathology* / Q000628:therapy*; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D016896:Treatment Outcome; D014467:Ultraviolet Therapy / Q000379:methods*
chemical_list: D007155:Immunologic Factors; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene